ITCI — Intra-Cellular Therapies Income Statement
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
- 62
- 13
- 87
- 54
Annual income statement for Intra-Cellular Therapies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 22.8 | 83.8 | 250 | 464 | 681 |
| Cost of Revenue | |||||
| Gross Profit | 20.9 | 75.8 | 230 | 431 | 624 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 254 | 369 | 514 | 624 | 798 |
| Operating Profit | -231 | -286 | -264 | -159 | -117 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -227 | -284 | -256 | -139 | -74.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -227 | -284 | -256 | -140 | -74.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -227 | -284 | -256 | -140 | -74.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -227 | -284 | -256 | -140 | -74.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.23 | -3.5 | -2.72 | -1.46 | -0.724 |